Clearside Biomedical, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • CLSD
  • 1d3.20%
  • 1w0.00%
  • 1m-24.56%
  • 1y17.27%
ATH
  • ATH Price$24.72
  • ATH Date2016-10-11
  • % since ATH-94.78%
  • % to ATH1,816.28%
ATL
  • ATL Price$0.59
  • ATL Date2019-09-03
  • % from ATL120.21%
  • Last Low Price$0.5858
  • Last Low Date2019-09-03
  • % From Last Low120.21%
IPO
  • IPO Price$8.00
  • % Current ROI USD-83.88%
  • ATH Price$24.72
  • % ROI ATH 421,987.03%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CLSD"]

Key Data [addtoany]

Current price $1.29
Sector Healthcare
Industry Biotechnology
Today's High/Low $1.3/$1.21
Volume 183,012.00
Previous Close $1.25
52 Week High/Low $2.12/$0.6501
Market Cap 93,401,376.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-0.56
Annualized Dividend $0
$1.29
[addtoany]

Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases.
Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial.
It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity